Blog - EverGlade Consulting

EverGlade Insights Blog

A New Direction: Host-Directed, Not Pathogen-Specific Unlike traditional antivirals or antibiotics, host-directed therapeutics (HDTs) focus on modulating the patient’s immune response rather than targeting a specific pathogen. This “threat-agnostic” approach is especially promising in an...

Advancing Chemical Threat Readiness: The MCDC’s New Call for Prototypes April 2025 marks another pivotal moment for U.S. defense readiness in chemical and biological threat detection. Through the Medical CBRN Defense Consortium (MCDC), the Army...

Why It Matters The rise of highly pathogenic avian influenza (HPAI) strains like H5N1, their spread to livestock, and increasing zoonotic infections in the U.S. has underscored the need for rapid, accurate immune assay infrastructure....

Key Takeaways from the April 2025 Executive Order On April 2, 2025, President Trump issued an Executive Order titled “Modernizing Defense Acquisitions and Spurring Innovation in the Defense Industrial Base.” This directive signals a major...

NSCEB Final Report: Charting the Future of Biotechnology in America The National Security Commission on Emerging Biotechnology (NSCEB) has released its final report, “Charting the Future of Biotechnology: An Action Plan for American Security and...

Strengthening America’s Defense: The Defense Innovation Unit’s Blue Manufacturing Initiative In an era where rapid technological advancement is crucial for national security, the Defense Innovation Unit (DIU) has launched the Blue Manufacturing Initiative. This strategic...

Contact Us

Stay informed about government funding opportunities.

Scroll to Top